COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition
From BugSigDB
Jump to:navigation, search
Study information
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI
Authors
Zhao S, Lok KYW, Sin ZY, Peng Y, Fan HSL, Nagesh N, Choi MSL, Kwok JYY, Choi EPH, Zhang X, Wai HK, Tsang LCH, Cheng SSM, Wong MKL, Zhu J, Mok CKP, Ng SC, Chan FKL, Peiris M, Poon LLM, Tun HM
Journal
NPJ vaccines
Year
2023
Newborns can acquire immunological protection to SARS-CoV-2 through vaccine-conferred antibodies in human breast milk. However, there are some concerns around lactating mothers with regards to potential short- and long-term adverse events and vaccine-induced changes to their breast milk microbiome composition, which helps shape the early-life microbiome. Thus, we sought to explore if SARS-CoV-2 mRNA vaccine could change breast milk microbiota and how the changes impact the levels of antibodies in breast milk. We recruited 49 lactating mothers from Hong Kong who received two doses of BNT162b2 vaccine between June 2021 and August 2021. Breast milk samples were self-collected by participants pre-vaccination, one week post-first dose, one week post-second dose, and one month post-second dose. The levels of SARS-CoV-2 spike-specific IgA and IgG in breast milk peaked at one week post-second dose. Subsequently, the levels of both antibodies rapidly waned in breast milk, with IgA levels returning to baseline levels one month post-second dose. The richness and composition of human breast milk microbiota changed dynamically throughout the vaccination regimen, but the abundances of beneficial microbes such as Bifidobacterium species did not significantly change after vaccination. Additionally, we found that baseline breast milk bacterial composition can predict spike-specific IgA levels at one week post-second dose (Area Under Curve: 0.72, 95% confidence interval: 0.58-0.85). Taken together, our results identified specific breast milk microbiota markers associated with high levels of IgA in the breast milk following BNT162b2 vaccine. Furthermore, in lactating mothers, BNT162b2 vaccines did not significantly reduce probiotic species in breast milk.
Experiment 1
Subjects
- Location of subjects
- China
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Breast , Milk Mamma,Mammary part of chest,Mammary region,Breast,Mammary gland milk,Milk
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- response to vaccine , timepoint response to vaccine,timepoint
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Mothers at pre-vaccination timepoint
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Mothers at post vaccination timepoints
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Breastfeeding mothers at post vaccination timepoints; one week post-first dose, one week post second-dose, one month post-second dose.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 44
- Group 1 sample size Number of subjects in the case (exposed) group
- 44
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- None
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V3-V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Statistical test
- LEfSe
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- 1.5
Alpha Diversity
- Chao1 Abundance-based estimator of species richness
- increased
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- unchanged
Signature 1
Source: figure 1g
Description: The most differentially abundant taxa in mothers throughout all post-vaccination timepoints; at one week post-first dose, one week post-second dose and one month post-second dose.
Abundance in Group 1: increased abundance in Mothers at post vaccination timepoints
| NCBI | Quality Control | Links |
|---|---|---|
| Acinetobacter ursingii | ||
| Roseomonas gilardii | ||
| unclassified Brevundimonas | ||
| unclassified Gordonia (in: high G+C Gram-positive bacteria) | ||
| unclassified Paracoccaceae |
Revision editor(s): Folakunmi
Signature 2
Source: figure 1g
Description: The most differentially abundant taxa in mothers throughout all post-vaccination timepoints; at one week post-first dose, one week post-second dose and one month post-second dose.
Abundance in Group 1: decreased abundance in Mothers at post vaccination timepoints
| NCBI | Quality Control | Links |
|---|---|---|
| Helicobacter rodentium | ||
| unclassified Allobaculum | ||
| unclassified Muribaculaceae | ||
| unclassified Ralstonia | ||
| unclassified Turicibacter |
Revision editor(s): Folakunmi
Experiment 2
Differences from previous experiment shown
Subjects
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- response to vaccine response to vaccine
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- mothers at pre-vaccination
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- High IgA mothers at one week post-second dose
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- breastfeeding mothers with high IgA at one week after receiving the second dose of the SARS-CoV-2 mRNA vaccine (BNT162b2).
- Group 1 sample size Number of subjects in the case (exposed) group
- 18
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- Not specified
Lab analysis
Statistical Analysis
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.004
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- Not specified
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- increased
- Chao1 Abundance-based estimator of species richness
- unchanged
Signature 1
Source: figure 2d
Description: differential abundance in baseline microbiota of mothers with high IgA at one week post second-dose of BNT162b2.
Abundance in Group 1: increased abundance in High IgA mothers at one week post-second dose
Revision editor(s): Folakunmi
Experiment 3
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- pre-vaccination (baseline)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- low IgA mothers at one week post-second dose
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- breastfeeding mothers with low IgA at one week after receiving the second dose of the SARS-CoV-2 mRNA vaccine (BNT162b2).
- Group 1 sample size Number of subjects in the case (exposed) group
- 25
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- decreased
- Chao1 Abundance-based estimator of species richness
- unchanged
Signature 1
Source: figure 2d
Description: differential abundance in baseline microbiota of mothers with low IgA at one week post second-dose of BNT162b2.
Abundance in Group 1: increased abundance in low IgA mothers at one week post-second dose
| NCBI | Quality Control | Links |
|---|---|---|
| unclassified Brevundimonas | ||
| unclassified Acinetobacter | ||
| Corynebacterium kroppenstedtii |
Revision editor(s): Folakunmi
Experiment 4
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Mothers at pre-vaccination timepoint
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Mothers at one week post-first dose
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Breastfeeding mothers at one week after receiving the first dose of BNT162b2 vaccine.
- Group 1 sample size Number of subjects in the case (exposed) group
- 44
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- None
Lab analysis
Statistical Analysis
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- 1.5
Alpha Diversity
- Chao1 Abundance-based estimator of species richness
- increased
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- unchanged
Signature 1
Source: supplementary table 3
Description: differential abundance of mothers one week after first dose of BNT162b2 when compared to baseline.
Abundance in Group 1: increased abundance in Mothers at one week post-first dose
Revision editor(s): Folakunmi
Experiment 5
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Mothers at pre-vaccination timepoint (baseline)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Mothers at one week post-second dose
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Breastfeeding mothers at one week post-second dose of BNT162b2 vaccine.
Lab analysis
Statistical Analysis
Alpha Diversity
- Chao1 Abundance-based estimator of species richness
- increased
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- unchanged
Signature 1
Needs review
Source: supplementary table 3
Description: differential abundance of mothers at one week post second dose of BNT162b2 when compared to baseline.
Abundance in Group 1: increased abundance in Mothers at one week post-second dose
Revision editor(s): Folakunmi, ChiomaBlessing
Experiment 6
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Mothers at pre-vaccination timepoint
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Mothers at one month post second-dose
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Breastfeeding mothers at one month post second-dose of BNT162b2 vaccine.
Lab analysis
Statistical Analysis
Alpha Diversity
- Chao1 Abundance-based estimator of species richness
- increased
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- unchanged
Signature 1
Needs review
Source: supplementary table 3
Description: differential abundance of mothers at one month post second dose of BNT162b2 when compared to baseline.
Abundance in Group 1: increased abundance in Mothers at one month post second-dose
Revision editor(s): Folakunmi, Chinelsy, ChiomaBlessing
Retrieved from "https://bugsigdb.org/w/index.php?title=Study_835&oldid=113643"
Hidden category:
